Estados financieros detallados de Revelation Biosciences, Inc. (REVB): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $0.92, REVB presenta beneficios negativos (P/E no significativo) y un ROE del -100.20%. La capitalización bursátil es de $4M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | $40008 | $25049 | $27923 | $27058 |
| Beneficio Bruto | 0 | 0 | 0 | -$40008 | -$25049 | -$27923 | -$27058 |
| I+D | 0 | $2.6M | $6.9M | $5.4M | $4.1M | $3.5M | $4.1M |
| Generales y Administrativos | $3638 | $1.2M | $5.0M | $5.5M | $4.5M | $4.4M | $5.0M |
| Gastos Operativos | $3638 | $3.8M | $12.0M | $10.9M | $8.7M | $8.0M | $9.1M |
| Beneficio Operativo | -$3638 | -$3.8M | -$12.0M | -$10.9M | -$8.7M | -$8.0M | -$9.1M |
| EBITDA | -$3638 | 0 | -$11.9M | -$10.8M | -$8.6M | -$7.9M | -$9.0M |
| Gastos por Intereses | 0 | 0 | $41759 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$3638 | -$3.8M | -$12.0M | -$10.8M | -$120254 | -$15.0M | -$8.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$3638 | -$1.6M | -$12.0M | -$10.8M | -$120254 | -$15.0M | -$8.9M |
| BPA | $-6.72 | $-9032.69 | $-20400.00 | $-9643.37 | $-8.41 | $-87.68 | $-23.95 |
| BPA Diluido | $-6.72 | $-9032.69 | $-20400.00 | $-9643.37 | $-8.41 | $-87.68 | $-23.95 |
| Acciones en Circulación (Diluidas) | $542 | $181 | $588 | $1123 | $14290 | $171510 | $620800 |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$6765 | -$5852 | -$7203 | 0 |
| Beneficio Operativo | -$1.9M | -$2.6M | -$3.1M | -$3.7M |
| EBITDA | -$1.9M | -$2.6M | -$3.1M | -$3.3M |
| Beneficio Neto | -$1.9M | -$2.5M | -$3.0M | -$3.3M |
| BPA | $-1.77 | $-1.65 | $-2.71 | $-0.87 |
| BPA Diluido | $-1.77 | $-1.65 | $-2.71 | $-0.87 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | 0 | $11734 | $1.3M | $5.3M | $12.0M | $6.5M | $10.7M |
| Inversiones a Corto | 0 | $525287 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | 0 | $651291 | $1.9M | $5.4M | $12.1M | $6.6M | $10.8M |
| Inmovilizado Material | 0 | 0 | $130141 | $90133 | $65084 | $56332 | $740355 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $22671 | $74.2M | $2.0M | $5.5M | $12.2M | $6.6M | $11.6M |
| Cuentas por Pagar | 0 | 0 | $596261 | $554205 | $1.4M | $783621 | $577501 |
| Deuda a Corto | 0 | 0 | $16752 | 0 | 0 | 0 | $23013 |
| Pasivos Corrientes | $26309 | $3.4M | $2.1M | $4.5M | $5.6M | $1.9M | $2.0M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $26309 | $6.3M | $2.1M | $4.5M | $5.6M | $1.9M | $2.7M |
| Reservas | -$3638 | -$5.7M | -$14.5M | -$25.3M | -$25.5M | -$40.5M | -$49.4M |
| Patrimonio Neto | -$3638 | $67.8M | -$99470 | $1.1M | $6.6M | $4.7M | $8.9M |
| Deuda Total | 0 | 0 | $16752 | 0 | 0 | 0 | $746784 |
| Deuda Neta | 0 | -$537021 | -$1.3M | -$5.3M | -$12.0M | -$6.5M | -$10.0M |
| Capital Circulante | -$26309 | -$2.8M | -$229611 | $948281 | $6.6M | $4.7M | $8.8M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $12.7M | $10.7M | $14.1M | $11.5M |
| Activos Totales | $12.9M | $11.6M | $15.0M | $12.5M |
| Pasivos Totales | $1.9M | $2.7M | $2.1M | $2.4M |
| Patrimonio Neto | $11.0M | $8.9M | $13.0M | $10.1M |
| Deuda Total | 0 | $746784 | $759044 | $739916 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$3638 | -$1.6M | -$12.0M | -$10.8M | -$120254 | -$15.0M | -$8.9M |
| Amortizaciones | 0 | 0 | $16782 | $25048 | $25049 | $27923 | $27058 |
| Compensación en Acciones | 0 | $43848 | $470878 | $301116 | $155721 | $168850 | $595368 |
| Cambio en Capital Circulante | $3638 | -$80497 | $356220 | -$730971 | $982135 | -$3.4M | -$6037 |
| Flujo de Caja Operativo | 0 | -$215074 | -$11.1M | -$11.2M | -$7.3M | -$18.3M | -$8.3M |
| Inversiones (CapEx) | 0 | $4 | -$131963 | 0 | 0 | -$19171 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | 0 | -$215070 | -$11.2M | -$11.2M | -$7.3M | -$18.3M | -$8.3M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$1.6M | -$2.0M | -$3.2M | -$2.6M |
| Inversiones (CapEx) | 0 | 0 | -$71879 | -$39628 |
| Flujo de Caja Libre | -$1.6M | -$2.0M | -$3.3M | -$2.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $874 | $370166 | $470997 | $401417 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -44718.6% | -635.2% | +9.7% | +98.9% | -12405.6% | +40.7% |
| Crecimiento BPA (anual) | | -134315.0% | -125.8% | +52.7% | +99.9% | -942.6% | +72.7% |
| Cambio en Acciones (anual) | | -66.7% | +225.5% | +91.1% | +1172.5% | +1100.2% | +262.0% |
| Crecimiento FCF (anual) | | | -5118.1% | +0.0% | +35.1% | -151.7% | +54.9% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $0.00 | $-1191.46 | $-19099.53 | $-9990.56 | $-509.89 | $-106.94 | $-13.32 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $542 | $181 | $588 | $1123 | $14290 | $171510 | $620800 |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -100.20% |
| Rentabilidad sobre capital invertido | -104.28% |
| Rentabilidad sobre activos | -86.02% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.07 |
| Ratio corriente | 6.21 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.21 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -97600.00 | -74.77 | -33.60 | -3.97 | -342.93 | -1.01 | -0.13 |
| P/VC | -97628.86 | 1.80 | -4048.98 | 40.89 | 6.20 | 3.22 | 0.22 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |